Michael Heffernan

6.9k citations

66 papers · 3.2k indexed · 1 hit paper · h-index 25

Impact in

Dermatology top 0.2%
- Dermatology and Skin Diseases
Immunology top 1%
- Psoriasis: Treatment and Pathogenesis

Papers in

Dermatology 19
- Dermatology and Skin Diseases 9
Pathology and Forensic Medicine 16
- Autoimmune Bullous Skin Diseases 12

Co-authors: Alan Menter Jeremy C. Smith Gregory S. Cameron J. Erickson Mark Lebwohl Daniel Braun Richard G. Langley Craig L. Leonardi
Journals: Canadian Journal of Cardiology (7 papers)Journal of the American Academy of Dermatology (6 papers)American Heart Journal (5 papers)Seminars in Cutaneous Medicine and Surgery (5 papers)Journal of the European Academy of Dermatology and Venereology (2 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Michael Heffernan

63 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials 2015 · 658 citations

Peers

Countries citing papers authored by Michael Heffernan

Since Specialization

Citations

This map shows the geographic impact of Michael Heffernan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Heffernan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Heffernan more than expected).

Fields of papers citing papers by Michael Heffernan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Heffernan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Heffernan. The network helps show where Michael Heffernan may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Heffernan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Heffernan Line = papers co-authored together Michael Heffernan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Intersection of Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: Recent Insights in a Challenging Area CJC Open ·Michael Heffernan, Samantha Rutherford	2025	3
2	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) Canadian Journal of Cardiology ·Yaron Arbel, Dennis T. Ko, Andrew T. Yan, Warren J. Cantor, Akshay Bagai, Maria Koh, María Eberg, Mary Tan, David Fitchett, Bjug Borgundvaag, John Ducas, Michael Heffernan, Laurie J. Morrison, Anatoly Langer, Vladimír Džavík, Shamir R. Mehta, Shaun G. Goodman	2018	9
3	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status Canadian Journal of Cardiology ·Nigel S. Tan, Shaun G. Goodman, Warren J. Cantor, Juan Russo, Bjug Borgundvaag, David Fitchett, Vladimír Džavík, Mary Tan, Basem Elbarouni, Shahar Lavi, Akshay Bagai, Michael Heffernan, Dennis T. Ko, Andrew T. Yan	2016	7
4	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials The Lancet ·C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp Hit paper breakdown →	2015	658
5	Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis The Journal of Rheumatology ·Mark C. Genovese, Daniel Braun, J. Erickson, Pierre‐Yves Berclaz, Subhashis Banerjee, Michael Heffernan, Hilde Carlier	2015	30
6	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis Journal of the American Academy of Dermatology ·Kenneth B. Gordon, Craig L. Leonardi, Mark Lebwohl, Andrew Blauvelt, Gregory S. Cameron, Daniel Braun, J. Erickson, Michael Heffernan	2014	87
7	Clinical outcomes and cost implications of routine early PCI after fibrinolysis: One-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) study American Heart Journal ·Akshay Bagai, Warren J. Cantor, Mary Tan, 藤雅文, André Lamy, David Fitchett, Eric A. Cohen, Shamir R. Mehta, Bjug Borgundvaag, John Ducas, Michael Heffernan, Vladimír Džavík, Laurie J. Morrison, Brian Schwartz, Charles Lazzam, Anatoly Langer, Shaun G. Goodman	2013	17
8	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) American Heart Journal ·Tae Sub Jung, Warren J. Cantor, Raymond T. Yan, Shamir R. Mehta, Laurie J. Morrison, Michael Heffernan, David Fitchett, Vladimír Džavík, John Ducas, Bjug Borgundvaag, Eric A. Cohen, Shaun G. Goodman, Andrew T. Yan	2012	9
9	The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Robert E. Kalb, Andrew Blauvelt, Michael Heffernan, Howard Sofen, Laura K. Ferris, Francisco A. Kerdel, Stephen Calabro, Jim J. Wang, Urs Kerkmann, Marc Chévrier	2011	45
10	Asymptomatic, Edematous Upper Lip in a 39-Year-Old Woman—Quiz Case Archives of Dermatology ·Kazutaka Obama, ავთანდილ გელაშვილი, John C. Moad, Michael Heffernan	2009	1
11	Crusted Violaceous Plaques on an Immunocompromised Host—Quiz Case Archives of Dermatology ·周瑞海, Celine Py, Michael Heffernan	2007	0
12	Adalimumab Treatment for Pyoderma Gangrenosum Archives of Dermatology ·Michael Heffernan	2007	41
13	Adalimumab for Treatment of Cutaneous Sarcoidosis Archives of Dermatology ·Michael Heffernan, Jeremy C. Smith	2006	56
14	Off-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (Part 1 of 2) Journal of the American Academy of Dermatology ·Jeremy C. Smith, P. Lohith Kumar, Michael Heffernan	2006	18
15	A Papule Arising in Irradiated Breast Tissue—Quiz Case Archives of Dermatology ·Anja Biemann, Dongsi Lu, Michael Heffernan	2006	1
16	A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris British Journal of Dermatology ·Michael Heffernan, 김유정, Milan J. Anadkat	2006	13
17	Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin British Journal of Dermatology ·Anthony Kulczycki, 김유정, Andrew Eisen, Michael Heffernan	2003	29
18	Facial signs of systemic disease Facial Plastic Surgery Clinics of North America ·김유정, Michael Heffernan	2003	3
19	A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis Nature Genetics ·Cynthia Helms, Li Cao, James G. Krueger, Ellen M. Wijsman, Francesca Chamian, Derek Gordon, Michael Heffernan, Jil Daw, Jason Robarge, Jürg Ott, Pui–Yan Kwok, Alan Menter, A. Bowcock	2003	237
20	Effects of exposure temperature on brown adipose tissue uncoupling protein mRNA levels Biochemistry and Cell Biology ·Karl B. Freeman, Michael Heffernan, Sara Knoblauch, Hasmukh V. Patel	1989	8

About Michael Heffernan

Michael Heffernan is a scholar working on Dermatology, Pathology and Forensic Medicine, Cardiology and Cardiovascular Medicine, Immunology and Periodontics, having authored 66 papers that have together received 3.2k indexed citations. Recurring topics across this work include Acute Myocardial Infarction Research (13 papers), Autoimmune Bullous Skin Diseases (12 papers), Coronary Interventions and Diagnostics (12 papers), Psoriasis: Treatment and Pathogenesis (10 papers), Cardiac Imaging and Diagnostics (9 papers), Dermatology and Skin Diseases (9 papers), Autoimmune and Inflammatory Disorders Research (4 papers) and Heart Failure Treatment and Management (4 papers). The work is most often cited by research in Dermatology (1.2k citations), Immunology (1.7k citations), Rheumatology (459 citations), Pathology and Forensic Medicine (520 citations) and Cardiology and Cardiovascular Medicine (593 citations). Michael Heffernan has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Alan Menter, Jeremy C. Smith, Gregory S. Cameron, J. Erickson, Mark Lebwohl, Daniel Braun, Richard G. Langley, Craig L. Leonardi, Martin M. Okun and Kenneth B. Gordon. Their work appears in journals such as Canadian Journal of Cardiology, Journal of the American Academy of Dermatology, American Heart Journal, Seminars in Cutaneous Medicine and Surgery and Journal of the European Academy of Dermatology and Venereology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact